Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109512 · ClinicalTrials.gov registry record · Phase 2
Endometriosis Trial: Study of NBI-56418 in Endometriosis
A Phase 2 study of Endometriosis, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 15
- Study locations
NCT00109512: Completed Phase 2 study of Endometriosis, sponsored by Abbott.
NCT00109512 is a Phase 2 study of Endometriosis that has completed, run by Abbott. The registered enrollment target is 76 participants, below the 263-participant average among 48 other Endometriosis trials with a reported enrollment target (71% lower). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00109512, a Phase 2 study of Endometriosis, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with subjects randomized to one of three treatment groups, placebo, 75 mg and 150 mg in a 1:1:1 ratio. Study drug was administered once daily for 12 weeks. After the last dose at the end of Week 12, follow-up continued every 4 weeks for 12 weeks.
Primary Outcome
This scale is used to assess the signs (pelvic tenderness and induration) and symptoms (nonmenstrual pelvic pain, dysmenorrhea and dyspareunia) associated with endometriosis.
Conditions Studied
Interventions
- DRUG placebo
- DRUG NBI-56418 (GnRH antagonist)
Study Locations (15)
Illinois
- Site Reference ID/Investigator# 56270 - Champaign
- Site Reference ID/Investigator# 56273 - Chicago
- Site Reference ID/Investigator# 56269 - Oak Brook
- Site Reference ID/Investigator# 56271 - Peoria
California
- Site Reference ID/Investigator# 55210 - San Diego
- Site Reference ID/Investigator# 55214 - San Ramon
Virginia
- Site Reference ID/Investigator# 56274 - Richmond
- Site Reference ID/Investigator# 55212 - Virginia Beach
Arizona
- Site Reference ID/Investigator# 56266 - Phoenix
Florida
- Site Reference ID/Investigator# 56267 - Clearwater
Kentucky
- Site Reference ID/Investigator# 56272 - Louisville
North Carolina
- Site Reference ID/Investigator# 55213 - Winston-Salem
Texas
- Site Reference ID/Investigator# 55211 - Arlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
What the finished NCT00109512 record still lists
NCT00109512 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 263-participant average among 48 other Endometriosis trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Endometriosis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00109512 lists 15 locations in 10 states (Illinois, California, Virginia).
Frequently Asked Questions
What is clinical trial NCT00109512 about?
NCT00109512 is a clinical study titled "Endometriosis Trial: Study of NBI-56418 in Endometriosis". This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with subjects randomized to one of three treatment groups, placebo, 75 mg and 150 mg in a 1:1:1 ratio. Study drug was administered once daily for 12 weeks. After the last dose at the end of Week 12, f...
What is the current status of trial NCT00109512?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2005-04. Estimated completion is 2006-06.
What conditions does trial NCT00109512 study?
This clinical trial studies the following conditions: Endometriosis.
What interventions are being tested in trial NCT00109512?
The interventions under investigation include: placebo (DRUG), NBI-56418 (GnRH antagonist) (DRUG).
Who is sponsoring clinical trial NCT00109512?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00109512 being conducted?
This trial has 15 study locations across Arizona, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometriosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00109512's enrollment target sits among peer trials
76 29th of 48 higher than 20 of 48 other Endometriosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometriosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET / MRI
RECRUITING · Phase 2
-
Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis
RECRUITING · Phase 2
-
Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers
RECRUITING · Phase 2
-
Glycemic Regulation as Endometriosis Adjunct Treatment
RECRUITING · Phase 2
-
The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial
COMPLETED · Phase 2
-
Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia